Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM9IU21)

Drug Name
LY 165,163 Drug Info
Synonyms PAPP; LY-165163
Cross-matching ID
PubChem CID
121930
ChEBI ID
CHEMBL92250
CAS Number
CAS 1814-64-8
TTD Drug ID
D0T4PS

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Tryptophan metabolism 2.01 0.00e+0 35/42 (83.33%) ALDH2;CYP1B1;CAT;...
Terpenoid backbone biosynthesis 1.99 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;FDPS;...
Histidine metabolism 1.92 3.83e-3 16/22 (72.73%) ALDH2;MAOB;MAOA;...
Steroid biosynthesis 1.90 5.74e-3 19/20 (95%) MSMO1;TM7SF2;LSS;...
Fatty acid degradation 1.89 6.89e-3 40/43 (93.02%) ALDH2;CPT1A;ACSL1;...
Viral protein interaction with cytokine and cytokine re... 1.89 5.74e-3 84/100 (84%) CXCL13;CCR2;CCL19;...
Steroid hormone biosynthesis 1.88 4.92e-3 43/61 (70.49%) AKR1C2;AKR1C1;AKR1C3;...
AMPK signaling pathway 1.87 5.74e-3 106/120 (88.33%) IRS2;CPT1A;CD36;...
Longevity regulating pathway 1.81 1.28e-2 90/151 (59.6%) IRS2;CRYAB;FOXO1;...
Metabolism of xenobiotics by cytochrome P450 1.80 1.15e-2 49/77 (63.64%) AKR1C1;GSTA4;CYP1B1;...
Adipocytokine signaling pathway 1.79 1.25e-2 64/69 (92.75%) IRS2;CPT1A;CD36;...
Insulin resistance 1.78 1.53e-2 96/108 (88.89%) IRS2;CPT1A;CD36;...
Selenocompound metabolism 1.76 1.68e-2 11/17 (64.71%) TXNRD1;PAPSS2;SCLY;...
Valine, leucine and isoleucine degradation 1.68 3.61e-2 42/48 (87.5%) ALDH2;HMGCS1;AOX1;...
Phagosome 1.68 3.44e-2 118/152 (77.63%) CD36;ITGAM;FCGR2B;...
Glutathione metabolism 1.68 3.52e-2 43/57 (75.44%) GSTA4;GSTP1;IDH1;...
Hypertrophic cardiomyopathy -1.79 3.41e-2 81/90 (90%) CACNA1S;ITGB8;TGFB2;...
Gastric acid secretion -1.80 4.05e-2 63/76 (82.89%) ATP1B4;ATP1B2;MYLK3;...
Insulin secretion -1.83 4.55e-2 75/86 (87.21%) ATP1B4;ATP1B2;CACNA1S;...
Cardiac muscle contraction -2.04 0.00e+0 64/87 (73.56%) ATP1B4;ATP1B2;CACNA1S;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H